bioMérieux and Moderna Collaborate to Advance individualized Cancer Therapies
bioMérieux has a long history of collaboration with Moderna, a biotechnology company that gained worldwide recognition during the COVID-19 pandemic for its rapid development of a mRNA-based vaccine. Today, this collaboration is helping accelerate the development of individualized cancer treatments.
During a recent visit to Moderna’s state-of-the-art manufacturing facility in Marlborough, Massachusetts, Michel Baguenault, CEO of Institut Mérieux, observed how bioMérieux’s diagnostic innovations are supporting Moderna’s oncology pipeline, including Phase 3 trials in melanoma and non-small cell lung cancer.
“This relationship exemplifies how innovation and collaboration can accelerate access to life-saving therapies,” said Michel Baguenault. “By working together with Moderna, we are not only supporting scientific advancement but also making a tangible impact on public health and patient outcomes worldwide.”
The collaboration, which began in 2017 with the installation of BACT systems at Moderna’s Cambridge, Massachusetts, site, has since evolved into a comprehensive diagnostic collaboration. Today, it includes BACT/ALERT® systems and VITEK® MS for microbial identification, supporting Moderna’s expanding global operations.
Moderna site at Marlborough, Massachussetts.
This is a testament to the strength of cross-functional teamwork at bioMérieux. From sales and service to scientific affairs and technical development, teams across the organization have worked in unison to meet Moderna’s evolving needs — including reducing batch release times and optimizing sterility testing processes.
As Moderna works to scale its operations globally, with new sites in Australia, Canada and the UK, bioMérieux is committed to supporting this growth with advanced automation and digital solutions. Together, the two companies are paving the way for more efficient delivery of individualized cancer therapies to patients around the world.
